German pharmaceutical firm Boehringer Ingelheim has selected Certara's D360 as its global drug discovery platform, which will help in sharing discovery data across global working groups that can include external collaborators.
Certara is a provider of software and scientific consulting services to enhance productivity and decision-making from drug discovery through drug development.
The German firm intends to install the global data mining tool at three of its sites including Ridgefield in Connecticut, US, Biberach in Germany and Vienna in Austria, where it is currently using different data sources, mining tools, and workflows for analyzing the information.
Certara vice president of scientific informatics Jonathan Feldmann said in addition to integrating data for easy access, D360 empowers researchers to query and analyze their data without support from the IT team.
"D360 enables researchers to quickly answer their questions as they conceive them, thus helping to shorten the drug discovery cycle," Feldmann said.
